Huo Zeng
Established on August 13, 2014, the company's business scope includes: biotechnology development services, consulting, exchange services and transfer services; Medical research and experimental development; Food science and technology research services; Medical information and technology consulting services; Medical device technology promotion service; Research and development of drugs, class I medical devices, class II medical devices, etc.
The company is a new drug R & D platform focusing on firstinclass and bestinclass, with broad international academic vision and keen insight into the most cutting-edge drug R & D and biomedical fields. The company is equipped with top returnee experts, with completely independent intellectual property rights. The team includes experts in cancer biology and target research and actual inventors of Kemena. It is a perfect combination of biomedicine and chemistry. All the achievements have applied for Chinese patent and are applying for international PCT. The company's pharmaceutical technology can be used alone for patients with prominent targets, and can be combined with conventional treatment and immunotherapy; It can be widely used in the treatment of hematological and solid tumors, as well as proliferative diseases.

Business demands: the company has an estimated value of 150 million yuan and plans to raise equity financing of 20 million yuan. The funds raised will be used to improve the international and domestic patent applications of the project; Establish an efficient and powerful operation team and a new drug R & D joint stock company; To conduct preclinical research on new projects of existing technology reserve.
He Liu
Founded in 2006, the group is a comprehensive large enterprise group rooted in Sichuan and Chongqing and developing in the whole country.
After more than ten years of high-quality development, as one of China's top 500 private enterprises, the group firmly takes "deep industrial operation + industrial investment" as the dual driving force, constantly tamps the industrial foundation, excels in strengthening the real economy, and builds a development pattern of industrial investment, collaborative merger and acquisition, and capital integration, so as to constantly stimulate its own vitality, Give full play to the advantages of various industrial sectors, and strive to achieve the strategic goals of asset scale, business nationalization and industrial cluster.
At present, the business scope of the group covers 13 provinces (cities) across the country. It is actively playing the synergy effect of industrial operation and capital operation, building a resource integration platform, and deeply arranging multiple core industries such as modern city operation, property and community operation, big health, cultural tourism, modern agriculture, energy, etc. As of 2019, the group has been rated as "top 100 real estate development enterprises in China" and "top 100 real estate enterprises in China" for four consecutive years. It has won the title of "top 100 brand value of real estate development enterprises in China" for three times and "top 10 brand value of real estate companies in Western China" for four times.
At the present stage, the group's big health sector focuses on clothing, food, housing and transportation, continuously strengthens R & D, M & A and expansion through the dual ways of endogenous growth and extension expansion, always takes "improving the quality of life, passing love and responsibility" as the corporate mission, and gradually establishes a big health industry pattern with medical manufacturing, medical care and medical services as the main body, and is committed to eliminating sub-health, health care and medical services Improve physical fitness, do a good job in health security, health management, health maintenance; Help people to establish a lifestyle of health care and disease prevention.

Business demands: the group's big health sector currently plans to raise 100 million yuan or increase 200 million yuan before listing.
Biomedical projects
Contact: 0755-82589687      E-mail: ruibo.wang@cscapital.net
Address: Room 910, Block B, Shenzhen International Chamber of Commerce Building, No.138 Fuhua 1st Road, Futian District, Shenzhen